Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | SOD1 | P00441 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251418 | 0.83 | TP53 (0.52) | TP53CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL30345364 | 0.83 | TP53 (0.52) | TP53CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL30935166 | 0.82 | ALDH1A1 (0.36) | TP53CYP3A4TSHRALDH1A1MAPT | |
| SCHEMBL16386132 | 0.82 | TSHR (0.49) | CYP3A4TSHRMAPTNPC1RAB9A | |
| SCHEMBL15219240 | 0.77 | NCF1 (0.49) | NCF1TSHRALDH1A1MAPTTDP1 | |
| SCHEMBL7627497 | 0.77 | MAPT (0.41) | TSHRALDH1A1MAPTSOD1 | |
| SCHEMBL30935134 | 0.76 | MAPT (0.51) | ALDH1A1MAPT | |
| SCHEMBL7931071 | 0.74 | MAOB (0.54) | ALDH1A1MAPTSOD1NPC1HPGD | |
| SCHEMBL6302587 | 0.74 | CYP3A4 (0.70) | NCF1TP53CYP3A4TSHRALDH1A1 | |
| SCHEMBL9770294 | 0.74 | NCF1 (0.44) | NCF1TP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127636-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | THE CLEVELAND CLINIC FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-11524945-B2 | Compounds for treating ILK-mediated diseases | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127636-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | ILK, ITGB1, ITGA2B | NCF1 1174/4885TP53 1446/4885CYP3A4 4847/4885 |
| US-11524945-B2 | Compounds for treating ILK-mediated diseases | ILK, ITGB1, ITGA2B | NCF1 1174/4885TP53 1446/4885CYP3A4 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.